Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study
- 1 February 2019
- journal article
- research article
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 54, 25-30
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: Systematic review and meta-analysisJournal of Allergy and Clinical Immunology, 2013
- The Role of IgE-Receptors in IgE-Dependent Airway Smooth Muscle Cell RemodellingPLOS ONE, 2013
- The potential of biologics for the treatment of asthmaNature Reviews Drug Discovery, 2012
- Clinical Benefits of 7 Years of Treatment with Omalizumab in Severe Uncontrolled AsthmaticsJournal of Asthma, 2011
- Acute exacerbations of asthma: epidemiology, biology and the exacerbation‐prone phenotypeClinical & Experimental Allergy, 2009
- Review: Omalizumab in the treatment of severe asthma: efficacy and current problemsTherapeutic Advances in Respiratory Disease, 2008
- IgE alone promotes human lung mast cell survival through the autocrine production of IL-6BMC Immunology, 2008
- Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthmaJournal of Allergy and Clinical Immunology, 2006
- High Prevalence of Skin Test Positivity in Severe or Difficult-to-Treat AsthmaJournal of Asthma, 2006
- The relationship between serum IgE and surface levels of FcϵR on human leukocytes in various diseases: Correlation of expression with FcϵRI on basophils but not on monocytes or eosinophilsJournal of Allergy and Clinical Immunology, 2000